Device and method for converting direct current into alternate current

The device for converting direct current into alternate current comprises a multilevel converter associated with at least a source of direct current and a modulation unit having piloting means for piloting the converter for the conversion of the direct current into an alternate output current, in which the modulation unit comprises comparison means for comparing the output current value with a preset positive threshold value and a preset negative threshold value, the piloting means being suitable for piloting the converter with a pulse modulation of the unipolar type in the event of the output current value being above the positive threshold value or below the negative threshold value and with a pulse modulation of the complementary type in the event of the output current value being below the positive threshold value and above the negative threshold value. The method for converting direct current into alternate current comprises a piloting phase of a multilevel converter for the conversion of a direct voltage into an alternate output voltage, a comparison phase of the output current value with a preset positive threshold value and a preset negative threshold value, the piloting phase being suitable for piloting the converter with a pulse modulation of the unipolar type in the event of the output current value being above the positive threshold value or below the negative threshold value and with a pulse modulation of the complementary type in the event of the output current value being below the positive threshold value and above the negative threshold value

Novel Harmonization Method for Multi-Centric Radiomic Studies in Non-Small Cell Lung Cancer

The purpose of this multi-centric work was to investigate the relationship between radiomic features extracted from pre-treatment computed tomography (CT), positron emission tomography (PET) imaging, and clinical outcomes for stereotactic body radiation therapy (SBRT) in early-stage non-small cell lung cancer (NSCLC). One-hundred and seventeen patients who received SBRT for early-stage NSCLC were retrospectively identified from seven Italian centers. The tumor was identified on pre-treatment free-breathing CT and PET images, from which we extracted 3004 quantitative radiomic features. The primary outcome was 24-month progression-free-survival (PFS) based on cancer recurrence (local/non-local) following SBRT. A harmonization technique was proposed for CT features considering lesion and contralateral healthy lung tissues using the LASSO algorithm as a feature selector. Models with harmonized CT features (B models) demonstrated better performances compared to the ones using only original CT features (C models). A linear support vector machine (SVM) with harmonized CT and PET features (A1 model) showed an area under the curve (AUC) of 0.77 (0.63-0.85) for predicting the primary outcome in an external validation cohort. The addition of clinical features did not enhance the model performance. This study provided the basis for validating our novel CT data harmonization strategy, involving delta radiomics. The harmonized radiomic models demonstrated the capability to properly predict patient prognosis

Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication

Background: The phase III CLinical Evaluation Of Pertuzumab And TRAstuzumab (CLEOPATRA) trial established the combination of pertuzumab, trastuzumab and docetaxel as standard first-line therapy for human epidermal growth factor receptor 2 (HER2)-positive locally recurrent/metastatic breast cancer (LR/mBC). The multicentre single-arm PERtUzumab global SafEty (PERUSE) study assessed the safety and efficacy of pertuzumab and trastuzumab combined with investigator-selected taxane in this setting. Patients and methods: Eligible patients with inoperable HER2-positive LR/mBC and no prior systemic therapy for LR/mBC (except endocrine therapy) received docetaxel, paclitaxel or nab-paclitaxel with trastuzumab and pertuzumab until disease progression or unacceptable toxicity. The primary endpoint was safety. Secondary endpoints included progression-free survival (PFS) and overall survival (OS). Prespecified subgroup analyses included subgroups according to taxane, hormone receptor (HR) status and prior trastuzumab. Exploratory univariable analyses identified potential prognostic factors; those that remained significant in multivariable analysis were used to analyse PFS and OS in subgroups with all, some or none of these factors. Results: Of 1436 treated patients, 588 (41%) initially received paclitaxel and 918 (64%) had HR-positive disease. The most common grade 653 adverse events were neutropenia (10%, mainly with docetaxel) and diarrhoea (8%). At the final analysis (median follow-up: 5.7 years), median PFS was 20.7 [95% confidence interval (CI) 18.9-23.1] months overall and was similar irrespective of HR status or taxane. Median OS was 65.3 (95% CI 60.9-70.9) months overall. OS was similar regardless of taxane backbone but was more favourable in patients with HR-positive than HR-negative LR/mBC. In exploratory analyses, trastuzumab-pretreated patients with visceral disease had the shortest median PFS (13.1 months) and OS (46.3 months). Conclusions: Mature results from PERUSE show a safety and efficacy profile consistent with results from CLEOPATRA and median OS exceeding 5 years. Results suggest that paclitaxel is a valid alternative to docetaxel as backbone chemotherapy. Exploratory analyses suggest risk factors that could guide future trial design

System and method for offsetting the input voltage unbalance in multilevel inverters or the like

The system for offsetting the input voltage unbalance in multilevel inverters or the like comprises a control unit operatively associated with a multilevel inverter for converting direct current into alternate current, the control unit being suitable for piloting the multilevel inverter for generating an output current depending on a reference current, and an equalisation unit for equalising the input voltages of the multilevel inverter having first generation means of a harmonic component of order equal to the reference current, out of phase with respect to the fundamental component of the reference current, detection means of the unbalance of the input voltages to the multilevel inverter, regulation means of the amplitude of the harmonic component depending on the detected unbalance, for offsetting the unbalance. The method for offsetting the unbalance of the input voltages in multilevel inverters or the like comprises a control phase of a multilevel inverter for converting direct current into alternate current, in which the multilevel inverter is piloted for generating an output current depending on a reference current, a generation phase of a harmonic component of order equal to the reference current, out of phase with respect to the fundamental component of the reference current, a detection phase of the unbalance of the input voltages to the multilevel inverter and a regulation phase of the amplitude of the harmonic component depending on the detected unbalance, for offsetting the unbalance

(Invited) Challenges and Opportunities in the Design of Tunnel FETs: Materials, Device Architectures, and Defects

session: Tunnel FETs and Strained bulk SOI "Finned" FETs (P7-1818)International audienc

Challenges and opportunities in the design of Tunnel FETs: materials, device architectures, and defects

Tunnel FETs are perceived as promising emerging devices to improve the energy efficiency of CMOS integrated circuits. This paper presents results and discussions about some selected topics concerning the working principles and design options of Tunnel FETs, which we believe will play an important role in the development and optimization of these transistors in the near term future

Emerging Role of Immunomonitoring to Predict the Clinical Outcome of Patients With Malignant Pleural Mesothelioma Treated With Radical Radiation Therapy

Purpose: The present study aimed at evaluating the baseline immune profile and the immunomodulating effects of radical hemithoracic radiation therapy (RT) in patients affected by malignant pleural mesothelioma (MPM) to identify potential predictive biomarkers of therapy response, toxicity development, and eligibility for further immunotherapeutic treatments. Methods and Materials: Blood samples were collected from 55 patients with MPM, enrolled in a phase 3 trial comparing radical hemithoracic RT (interventional arm, n = 28) with local palliative RT (control arm, n = 27). Immunomonitoring was performed before RT, at the end of treatment, and 1 month after therapy, characterizing natural killer cells, B and T lymphocytes, activated CD4 and CD8 T cells, interferon-γ- and tumor necrosis factor-α-producing T helper (Th) 1 cells, regulatory T cells, and Th17 and Th22 lymphocytes, through flow cytometry. Serum levels of interleukin (IL)-6, -8, -10 and mesothelin were quantified through Enzyme-Linked Immunosorbent Assay (ELISA) assays at the same time points. Variations in the immune parameters were investigated by Friedman test and Wilcoxon signed rank post hoc test with Bonferroni correction for multiple testing, while the prognostic effect of immune biomarkers was evaluated through Kaplan-Meier method and Spearman's correlation analysis. Results: Major immune variations were noticed after radical RT compared with palliative treatment, in particular an improvement in activated T cells and in interferon-γ-producing Th1 cells after RT. In the interventional arm, baseline high levels of Th22 and IL-10 and an increase in T cells were associated with an improved survival, whereas a fold increase in serum mesothelin correlated with the development of severe toxicity. An improvement of immunosuppressive regulatory T cells was observed in both arms of treatment. Conclusions: The immunomonitoring performed in patients with MPM revealed potential prognostic biomarkers for radical hemithoracic RT treatment and identified specific immune signatures induced by RT immunomodulation, which could suggest a synergistic effect with an immunotherapeutic treatment